Unraveling the genomic determinants of response to CDK4/6 inhibitors

por Litchfield, Lacey M., Webster, Vue W., Buchanan, Sean G.
Publicado 2018

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells

por Litchfield, Lacey M., Boehnke, Karsten, Brahmachary, Manisha, Mur, Cecilia, Bi, Chen, Stephens, Jennifer R., Sauder, J. Michael, Gutiérrez, Sonia M., McNulty, Ann M., Ye, Xiang S., Wu, Wenjuan, Lallena, María José, Gong, Xueqian, Merzoug, Farhana F., Jansen, Valerie M., Buchanan, Sean G.
Publicado 2020

Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders

por Wu, Xuewei, Yang, Xiaobao, Xiong, Yan, Li, Ruitong, Ito, Takahiro, Ahmed, Tamer A., Karoulia, Zoi, Adamopoulos, Christos, Wang, Hong, Wang, Li, Xie, Ling, Liu, Jing, Ueberheide, Beatrix, Aaronson, Stuart A., Chen, Xian, Buchanan, Sean G., Sellers, William R., Jin, Jian, Poulikakos, Poulikos I.
Publicado 2021

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft mo...

por Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.
Publicado 2012